IL312308A - Antibodies that bind to the A2 domain of factor XI and their uses - Google Patents

Antibodies that bind to the A2 domain of factor XI and their uses

Info

Publication number
IL312308A
IL312308A IL312308A IL31230824A IL312308A IL 312308 A IL312308 A IL 312308A IL 312308 A IL312308 A IL 312308A IL 31230824 A IL31230824 A IL 31230824A IL 312308 A IL312308 A IL 312308A
Authority
IL
Israel
Prior art keywords
domain
factor
methods
binding antibodies
antibodies
Prior art date
Application number
IL312308A
Other languages
English (en)
Hebrew (he)
Inventor
Dan Chalothorn
Kehdih Lai
Lori Morton
Original Assignee
Regeneron Pharma
Dan Chalothorn
Kehdih Lai
Lori Morton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Dan Chalothorn, Kehdih Lai, Lori Morton filed Critical Regeneron Pharma
Publication of IL312308A publication Critical patent/IL312308A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL312308A 2021-10-22 2022-10-21 Antibodies that bind to the A2 domain of factor XI and their uses IL312308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163270629P 2021-10-22 2021-10-22
PCT/US2022/078530 WO2023070097A2 (en) 2021-10-22 2022-10-21 Factor xi a2 domain-binding antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
IL312308A true IL312308A (en) 2024-06-01

Family

ID=84360943

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312308A IL312308A (en) 2021-10-22 2022-10-21 Antibodies that bind to the A2 domain of factor XI and their uses

Country Status (12)

Country Link
US (1) US12304969B2 (https=)
EP (1) EP4419142A2 (https=)
JP (1) JP2024539157A (https=)
KR (1) KR20240099304A (https=)
CN (1) CN118414168A (https=)
AU (1) AU2022368930A1 (https=)
CA (1) CA3235457A1 (https=)
CL (1) CL2024001237A1 (https=)
CO (1) CO2024006258A2 (https=)
IL (1) IL312308A (https=)
MX (1) MX2024004849A (https=)
WO (1) WO2023070097A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8388959B2 (en) 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
TWI736575B (zh) * 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
CA3125303A1 (en) 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof

Also Published As

Publication number Publication date
EP4419142A2 (en) 2024-08-28
CN118414168A (zh) 2024-07-30
KR20240099304A (ko) 2024-06-28
CL2024001237A1 (es) 2024-09-13
WO2023070097A2 (en) 2023-04-27
AU2022368930A1 (en) 2024-05-02
US12304969B2 (en) 2025-05-20
US20230131338A1 (en) 2023-04-27
MX2024004849A (es) 2024-05-06
CA3235457A1 (en) 2023-04-27
WO2023070097A3 (en) 2023-06-08
CO2024006258A2 (es) 2024-06-27
JP2024539157A (ja) 2024-10-28

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL282856A (en) Activatable anti-CD166 antibodies and methods of using them
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
HUE072193T2 (hu) Antitest kompozíciók és eljárások azok felhasználásához
SI4200018T1 (sl) Protitelesa proti-PAR-2 in postopki njihove uporabe
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL316368A (en) Anti-TL1A antibodies and methods of using them
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL298668B1 (en) Anti-CD200R1 antibodies and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
IL315845A (en) Anti-dectin-1 antibodies and methods of using them
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL317690A (en) Anti-GPNMB antibodies and methods of using them
IL308260A (en) Antibodies against Tigit and methods of using them
IL318694A (en) Antibodies against CCR8 and methods of using them
ZA202105152B (en) Anti-elastin antibodies and methods of use
IL312308A (en) Antibodies that bind to the A2 domain of factor XI and their uses
HK40116027A (en) Factor xi a2 domain-binding antibodies and methods of use thereof
IL308683A (en) Peptides and methods of use
IL320397A (en) Antibodies binding to the catalytic domain of factor XI and methods of using them
IL325937A (en) AAV-delivered antibodies and methods of using them
IL318357A (en) ANTI-IL27R antibodies and methods of using them
IL316894A (en) ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF
HK40115022A (en) Anti-cd300lb antibodies and methods of use thereof